http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2541810-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_85087458476a429eab94b15f28d7b5c4 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-00 |
| filingDate | 2013-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50994c5badc266262514670c883f567b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63c12b4f0ad6138ed6325919828b0ecd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77623125e0bc929a72ae5a6d01bb6451 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b45ef90b31aa7f4f8462c767e1ae3b3b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8bc7eca7ddcc6c97ea67f7bf7f3655e7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4cc5bb4f66ade4de83e7d3dd6e37affb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ccf361b80d530a6631f99348f83cbc0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c249ffe8c0bf07d726da2db0fff9aedd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04ac5cae2c8f7229d9cabdc52e02b638 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e30cc4392eece13ea6d661b3bc43c89f |
| publicationDate | 2015-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2541810-C2 |
| titleOfInvention | Method of treating prostate cancer with using prolonged prodrug of octreotide accompanying surgical or drug-induced castration |
| abstract | FIELD: medicine. n SUBSTANCE: invention refers to medicine, particularly to oncourology, and can be used in the non-surgical treatment of the patients suffering early stages of prostate malignant tumour. A method of treating prostate cancer with using prolonged prodrug of octreotide accompanying surgical or drug-induced castration involves a) measuring pre-therapeutic prostate-specific antigen; b) measuring pre-therapeutic blood plasma chromogranin A; c) selecting the patients having high blood chromogranin A of more than 3 nmol/l; d) conducting a therapy with prolonged prodrug of octreotide in a combination with dexamethasone in the selected patients; e) controlling the prostate-specific antigen variation every month and monitoring a decrease thereof in the patients by measuring it intra-therapeutically according to the stage d); the therapeutic efficacy according to the stage d) is evaluated by a therapeutic response, which is accompanied by maximum decrease of the prostate-specific antigen. n EFFECT: invention enables providing the higher therapeutic efficacy in the patients suffering prostate cancer at the different stages. n 3 cl, 1 tbl, 5 ex |
| priorityDate | 2013-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 50.